Selective, targeted laser treatment effective in patients with diabetes

VIENNA — Initial experience with the 577 nm subthreshold yellow Pascal laser in patients with diabetes shows that the technology may provide selective, targeted treatment with minimal damage to surrounding areas and reduced side effects. “Diabetics need treatment for life, usually from a young age, and we need minimal laser to stabilize the condition at every recurrence,” Paulo Stanga, MD, said at the Advanced Retinal Therapy meeting.

Full Story →